CPQ and neoplasm: Once in tumor cells, the aminopeptidase fusion domain of Melflufen can be affected by aminopeptidase and lipase, and the hydrophilic alkylating agent melphalan is further released to inhibit the DNA reparation and angiogenesis during therapy.